![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Efficacy and safety of doravirine/islatravir (100 mg/0.75 mg) once daily in heavily treatment-experienced persons with HIV-1: Week 49 results from a phase 3 trial
|
|
|
EACS 2023 Oct 18-21 Warsaw
Rosie Mngqibisa1; Ilsiyar Khaertynova2; Princy N. Kumar3; Andrew Carr4; Shariq Haider5; Ying Zhang6;
Todd Correll6; Ernest Asante-Appiah6; Wayne Greaves6*
1Enhancing Care Foundation, King Edward Hospital, Durban, South Africa; 2Kazan State Medical Academy, Kazan, Russia; 3Georgetown University, Washington, DC, USA; 4St Vincent's Hospital, Sydney, NSW, Australia; 5McMaster University, Hamilton, ON, Canada; 6Merck & Co., Inc., Rahway, NJ, USA
*Presenting author
An employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, at the time of the study
![1023231](../images/102323/102323-4/1023231.gif)
![1023232](../images/102323/102323-4/1023232.gif)
![1023233](../images/102323/102323-4/1023233.gif)
![1023234](../images/102323/102323-4/1023234.gif)
![1023235](../images/102323/102323-4/1023235.gif)
![1023236](../images/102323/102323-4/1023236.gif)
![1023237](../images/102323/102323-4/1023237.gif)
![1023238](../images/102323/102323-4/1023238.gif)
![1023239](../images/102323/102323-4/1023239.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|